In searching for anti-inflammatory agents from Australian medicinal plants, a method of selecting plants with antiinflammatory potential for chemical and pharmacological study was developed and is described in this paper. The method was based on the cross-referencing of ethnopharmacological information documented in Australian bush medicine and Chinese herbal medicine. Our hypothesis was that plants that have been used in several geographically different cultures for the same or similar medicinal purposes would be highly probable to possess some common chemical and pharmacological properties, and therefore might warrant scientific investigation. The Chinese ethnopharmacological information was used as "standard" references to select Australian plants with anti-inflammatory potential. From 284 plants documented in Australian bush medicine and 882 plants in Chinese herbal medicine, 58 Australian plants and 41 Chinese plants were identified to have potential anti-inflammatory activity. The traditional use of the identified Australian and Chinese plants to treat inflammatory conditions, botanical names, modes of preparation and administration, and chemical constituents were compiled to form a Chinese and an Australian dataset using Microsoft Access. By cross-referencing the ethnobotany, ethnopharmacology and phytochemistry of the plants in the two datasets, fourteen Australian plants were selected for laboratory study. Testing of these plants with respect to inhibitory activity against cyclooxygenases (COX) and lipoxygenases (LOX) showed that the majority of the plants (>85%) exhibited anti-inflammatory activity. Bioassay-guided isolation and spectroscopic identification of active constituents in three species were conducted. Racemosic acid was characterised as a new compound with anti-inflammatory activity from Ficus racemosa, together with a known compound bergenin. Triterpene-fatty acid esters were identified in Tinospora smilacina. HPLC fractions from Clematis pickeringii inhibited COX and LOX and also triggered peroxisome proliferator activated receptors (PPARs). This method of cross-referencing ethnopharmacological information to select plants with anti-inflammatory potential appears to be productive, and may be more widely applicable for the selection of plants for other pharmacological and chemical studies.
Advances in science, technology and medicine have enabled us to understand the mechanism of action of traditional herbal medicines and provided a basis for their rational use. The isolation, identification and biological tests of a range of active constituents in plant medicines not only confirm the wisdom of our ancestors in selecting plants for their medicinal use, but also generate an array of novel molecules directly as therapeutic agents or as lead compounds for designing better therapeutics. So far, of the estimated 422,000 species on the earth, only about 60,000 (14%) flowering plants have been collected and studied for active medicinal constituents [1] . Developing effective methods to select plants from the vast resources for chemical and pharmacological study has been a challenge for natural products chemists and pharmacologists.
A random selection of plant species may be an easy way but subsequent laboratory or clinical investigations may not be fruitful and cost-effective. Targeted plant selection is a better approach and warrants time and effort. Selecting a plant for study is the first critical step of research and should be undertaken as seriously as laboratory and clinical investigation. Several targeted methods, criteria and strategies have been developed, for instance, selection based on traditional usage, poisonous plants, selection based on chemical composition, screening for a specific biological activity and combination of several strategies [2] . Here we report a systematic method of selecting plants with antiinflammatory potential by cross-referencing the Chinese and Australian ethnopharmacological information documented in Chinese herbal medicine and the Australian bush medicine. Here the antiinflammatory plants in the ethnomedical context mean the use of crude plant products to treat diseases of inflammatory nature such as asthma, arthritis, rheumatism, edema, infections, snakebite, fever and headache.
The rationale for using this method is that if a particular plant has been used in several geographically different cultures for the same or similar medicinal purposes, the plant is highly probable to possess some real chemical and pharmacological properties of interest, and therefore warrants a scientific investigation. This strategy is particularly useful for the less well known and under utilized medicinal plants. We used the rich ethnopharmacological information documented in the Chinese herbal medicine as "standard" references to systematically select Australian plants with anti-inflammatory potential for laboratory study. The use of Chinese herbal medicine as a "standard" reference has been applied to understand and systematise the Brazilian popular Phytotherapy [3] .
Our group has been particularly interested in developing anti-inflammatory agents from Chinese and Australian plants [4, 5] . Our study reported that nine vine plants used in traditional Chinese medicine for the treatment of arthritis, rheumatoid arthritis and other inflammatory conditions possessed antiinflammatory activity measured by their inhibition on at least one of phospholipases, cyclooxygenases and lipoxygenses, which resulted in the blockage of inflammatory mediators such as prostaglandins and leukotrienes [4] . Initially we used these antiinflammatory Chinese vines as "standard" references to source Australian vine plants which may possess anti-inflammatory potential for further studies. Later we generalised this approach of cross-referencing ethnopharmacological information to systematically select all possible Australian plants with antiinflammatory potential for laboratory studies. This method is depicted in Scheme 1.
In this Scheme, two key processes are used. Process I afforded forty-one Chinese (coded with C01 to C41, see the Supplementary data) and fifty-eight Australian species (coded with A01 to A58, see the Supplementary data), which were selected from about 882 species in the Chinese herbal medicine and about 284 species in the Australian bush medicine respectively. In Process II, the 58 Australian species were further narrowed down to 14 species by cross comparison of their ethnopharmacological information with the Chinese references in two steps. In the first step key ethnopharmacological information of 41 Chinese and 58 Australian plants were entered into two databsets, Caip and Aaip respectively, using Microsoft Access [6] . The key ethnopharmacological information in the datasets include botanical name, common name, Chinese name, part used, therapeutic application, preparation, administration, and chemical constituents. In the second step the ethnobotany, ethnomedicine and phytochemistry in the two datasets were compared and analysed. This led to the selection of 14 Australian plants and 15 Chinese referencing plants ( Table 1 ).
The Process II in the Scheme 1 also generated small and specific subsets of Australian and Chinese plants ( Table 2 and Table 3 ). In Table 2 , the same species with similar therapeutic applications were selected. They were Achyranthes aspera, Abrus precatorius and Verbena officinalis. A. precatorius is not native to Australia, but it has been described as an Australian medicinal plant with antiseptic and bactericide properties [19] . In Table 3 , different species but belonging to the same genus and having similar therapeutic applications were selected as a subset of 7 Australian species for further studies. Of 14 selected Australian plants, 13 were collected and screened for their inhibitory activity against cyclooxygenase-1 at a concentration of ethanol extract 3.4 mg/ml [5] . Nine out of 13 (69.3%) show high (>70%) inhibition, 2 (15.3%) medium (70-30%) inhibition and 2 (15.3%) low (<30%) inhibition.
Three Australian plants, Ficus racemosa, Tinospora smilacina and Clemetis pickeringii, with high inhibition of COX-1 were further studied for cyclooxygenase-2, 5-lipoxygenase and phospholipase A 2 inhibition, cytotoxicity and phytochemical studies. Anti-inflammatory activities of the extracts from these species were confirmed and active principles were identified using bioassay-guided fractionation and spectroscopic techniques in the subsequent chemical and pharmacological investigation [7] [8] [9] . Racemosic acid (Figure 1 ) from F. racemosa was identified as a novel compound and possessed potent anti-inflammatory activities [7] . Total synthesis of racemosic acid has not been reported so far. A known compound bergenin also was identified from F. racemosa [7] . Triterpene-fatty acid esters were identified in Tinospora smilacina [8] . HPLC fractions from Clematis pickeringii inhibited COX and LOX, and also activated peroxisome proliferator activated receptors (PPARs) [9] .
We have described a systematic method of selecting Australian plants with anti-inflammatory potential for further studies through cross-cultural comparison of ethnobotanical, ethnomedical and phytochemical information in the Chinese herbal medicines and the Australian bush medicines recorded in two datasets using Microsoft Access.
Lin et al. were identified as the same species or different species but from the same genus to the Chinese plants with anti-inflammatory potential. This is not surprising if we consider the classical example of plant medicines, anticholinergic tropane alkaloid containing plants which exist in five plant families [10] . So far the extracts of 14 Australian plants have shown strong inhibition of cyclooxygenases, lipoxygenases and phospholipases and some active principles have been isolated and characterised. More active constituents from these plants are being analysed and identified.
The cross ethnopharmacological method of selecting plants for anti-inflammatory properties using Chinese herbal medicines as references may be applied to select plants with other biological properties from different countries or cultures. Interestingly, ethnopharmacological information was used for correlating the pertinent published chemical and biological information to prioritise plant collection for anticancer drug development [11] . Recently ethnopharmacological information was coupled with functional genomics to make plant drug discovery competitive with combinatorial chemistry [12] .
A limitation of this plant-selection method is its dependence on the available and documented ethnopharmacological information of plants. We have not compared the differences in enzymeinhibition screening of extracts from plants selected by this targeted method with a random selection method. The random plant collection was predominated at the National Cancer Institute (NCI) program in the period 1960-1986 when 35,000 plant species were screened against the P-388 lymphocytic leukemia assays in mice, or in vitro or KB carcinogema of nasopharynx in cell culture [11] . It was found that 2935 species (8.4%) contained active components, which is very low.
Experimental

Identifying and recording Chinese antiinflammatory plants (Caip dataset):
Medicinal plants or herbs used in the traditional Chinese medicine for the treatment of arthritis, rheumatoid arthritis, asthma, pain, fever, and other inflammatory conditions were identified and obtained through the sources of Chinese publications [13, 14] , English literature [15, 16] , and Dr P.J. Zhang, a traditional Chinese herbalist in Brisbane.
Key ethnopharmacological information was recorded and entered into a Chinese anti-inflammatory plants dataset (Caip dataset) using the Microsoft Access program. The Caip dataset contains a unique code, plant family name, genus, species, Chinese name, botanical identification, habitat, part used, collection, preparation, administration, herbal property, therapeutic applications (with a focus on treatment of inflammation), chemical constituents and references.
Identifying and recording Australian antiinflammatory plants (Aaip dataset):
Medicinal plants or herbs used in the Australian aboriginal medicine for the treatment of arthritis, rheumatic or rheumatoid arthritics, headache, pain snake bite, infection and other inflammatory conditions were identified and obtained through the publications of the Aboriginal Communities of the Northern Territory of Australia [17] , the Conservation
